Information Provided By:
Fly News Breaks for October 18, 2019
ICPT
Oct 18, 2019 | 06:37 EDT
Credit Suisse analyst Martin Auster lowered his price target for Intercept to $87 from $167, saying that while is he roughly in line with consensus for Ocaliva revenues in Q3, investor focus is likely to remain on the regulatory path forward for OCA in NASH, advances on non-invasive diagnostics, overall launch preparation and potential for sustainable pricing differentiation. Auster tells investors in a research note that he expects the stock will continue to be heavily debated, with a clearer picture on potential payer requirements for confirmed diagnosis and reimbursement, and pricing in NASH being the key events to provide better visibility into the potential launch trajectory and overall opportunity.
News For ICPT From the Last 2 Days
There are no results for your query ICPT